Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharming Group N.V (PHAR) Investment Income: 2019-2024

Historic Investment Income for Pharming Group N.V (PHAR) over the last 6 years, with Dec 2024 value amounting to -$6.1 million.

  • Pharming Group N.V's Investment Income fell 411.72% to -$9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.3 million, marking a year-over-year increase of 511.11%. This contributed to the annual value of -$6.1 million for FY2024, which is 203.57% down from last year.
  • Per Pharming Group N.V's latest filing, its Investment Income stood at -$6.1 million for FY2024, which was down 203.57% from $5.9 million recorded in FY2023.
  • Pharming Group N.V's 5-year Investment Income high stood at $5.9 million for FY2023, and its period low was -$14.8 million during FY2021.
  • Over the past 3 years, Pharming Group N.V's median Investment Income value was -$6.1 million (recorded in 2024), while the average stood at -$3.5 million.
  • Its Investment Income has fluctuated over the past 5 years, first slumped by 99,070.31% in 2021, then soared by 157.14% in 2023.
  • Yearly analysis of 5 years shows Pharming Group N.V's Investment Income stood at $14,956 in 2020, then plummeted by 99,070.31% to -$14.8 million in 2021, then spiked by 30.08% to -$10.3 million in 2022, then skyrocketed by 157.14% to $5.9 million in 2023, then plummeted by 203.57% to -$6.1 million in 2024.